Spitzer, Hannah http://orcid.org/0000-0002-7858-0936
Berry, Scott http://orcid.org/0000-0002-1838-4976
Donoghoe, Mark http://orcid.org/0000-0003-0212-6443
Pelkmans, Lucas
Theis, Fabian J. http://orcid.org/0000-0002-2419-1943
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (031L0210A, 031L0210A)
Helmholtz Association Initiative and Networking Fund through Helmholtz AI
Human Frontier Science Program (LT000238/2017-L)
Department of Education and Training | Australian Research Council (DE230100271)
University of New South Wales
Universität Zürich
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_192622)
European Research Council
Article History
Received: 12 May 2022
Accepted: 25 April 2023
First Online: 29 May 2023
Competing interests
: F.J.T. consults for Immunai Inc., Singularity Bio B.V., CytoReason Ltd and Omniscope Ltd, and has ownership interest in Dermagnostix GmbH and Cellarity. L.P. has filed a patent on the 4i technology, which is used in this manuscript (patent WO2019207004A1), and consults for Dewpoint Therapeutics and has ownership interest in Sagimet Biosciences and Apricot Therapeutics. All other authors have no competing interests.